Format

Send to

Choose Destination
See comment in PubMed Commons below
Ann Hematol. 2014 Mar;93(3):493-8. doi: 10.1007/s00277-013-1882-2. Epub 2013 Aug 15.

Breakthrough invasive fungal diseases during echinocandin treatment in high-risk hospitalized hematologic patients.

Author information

1
Department of Medicine, Queen Mary Hospital, Professorial Block, Pokfulam Road, Hong Kong, China.

Abstract

The frequency of breakthrough invasive fungal diseases (IFDs) during echinocandin therapy is unclear. We retrospectively analyzed 534 hematologic patients treated with echinocandin (caspofungin, N = 55; micafungin, N = 306; anidulafungin, N = 173). Four proven IFDs were found, caused by Candida parapsilosis (N = 2), C. parapsilosis and Candida glabrata (N = 1), and Fusarium species (N = 1). Four cases of possible IFDs were observed, all showing pulmonary infection. One case showed features suggestive of hepatosplenic candidiasis. Six of these eight cases had previously received the purine analog clofarabine. Breakthrough IFD during echinocandin treatment occurred infrequently (1.5 %), caused predominantly by Candida species. Clofarabine usage was an important risk factor.

PMID:
23949318
DOI:
10.1007/s00277-013-1882-2
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center